FABRICATION AND SCREENING OF SOLID LIPID NANOPARTICLES-LOADED MICRONEEDLE PATCH FOR POLYCYSTIC OVARY SYNDROME TREATMENT
DOI:
https://doi.org/10.22159/ajpcr.2025v18i7.54740Keywords:
Nanoparticles, Microneedle, Transermal drug delivery,, Animal study, clomiphene citrate.Abstract
Objectives: The study aimed to develop a novel microneedle (MN) patch for the transdermal delivery of clomiphene citrate. This approach seeks to facilitate sustained drug release through the skin, improving therapeutic efficacy and minimizing side effects associated with oral administration.
Methods: The patch was constructed using biocompatible polymers – polyvinyl alcohol, polyvinylpyrrolidone, and polyethylene glycol 400 – commonly utilized in medical applications. Each MN measured approximately 915 μm in height, optimized to penetrate the outer skin layer without causing pain. Durability was assessed by folding the patch repeatedly; it withstood nearly 300 folds before exhibiting signs of wear. Analytical tests confirmed that clomiphene citrate remained stable within the patch matrix, with no adverse interactions between the drug and the polymer components. In vitro experiments using simulated human skin models demonstrated a biphasic release pattern: an initial rapid release followed by a sustained release over 5 days. Human skin samples were employed to evaluate the patch’s drug release profile, corroborating the in vitro findings. The patch’s efficacy was tested on rats with letrozole-induced fertility issues, simulating human infertility conditions.
Results: Microscopic examination revealed uniformly shaped MNs of appropriate dimensions for effective skin penetration without discomfort. The patch demonstrated high durability, maintaining structural integrity after extensive mechanical stress. The drug and polymer components exhibited compatibility, ensuring the stability of clomiphene citrate within the patch. Approximately 89% of the drug was released over 5 days in vitro, while ex vivo tests showed a 78% release, indicating effective sustained delivery. In vivo studies indicated that the transdermal delivery of clomiphene citrate through the MN patch (MNP) resulted in prolonged drug activity and reduced side effects compared to oral administration.
Conclusion: The MNP developed in this study offers a promising alternative for the transdermal delivery of clomiphene citrate. Its design ensures painless application, sustained drug release, and improved therapeutic outcomes, potentially reducing the side effects associated with traditional oral administration.
Downloads
References
Hampton T. Researchers test microneedles for vaccine delivery. JAMA. 2005;293(16):2083.
Wermeling DP, Banks SL, Hudson DA, Gill HS, Gupta J, Prausnitz MR, et al. Microneedles permit transdermal delivery of a skin-impermeant medication to humans. Proc Natl Acad Sci U S A. 2008;105(6):2058-63. doi: 10.1073/pnas.0710355105, PMID 18250310
Lee JW, Choi SO, Felner EI, Prausnitz MR. Dissolving microneedle patch for transdermal delivery of human growth hormone. Small. 2011;7(4):531-9. doi: 10.1002/smll.201001091, PMID 21360810
Sullivan SP, Koutsonanos DG, Del Pilar Martin M, Lee JW, Zarnitsyn V, Choi SO, et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med. 2010;16(8):915-20. doi: 10.1038/nm.2182, PMID 20639891
Chu LY, Prausnitz MR. Separable arrowhead microneedles. J Control Release. 2011;149(3):242-9. doi: 10.1016/j.jconrel.2010.10.033, PMID 21047538
Gupta J, Gill HS, Andrews SN, Prausnitz MR. Kinetics of skin resealing after insertion of microneedles in human subjects. J Control Release. 2011;154(2):148-55. doi: 10.1016/j.jconrel.2011.05.021, PMID 21640148
Gill HS, Denson DD, Burris BA, Prausnitz MR. Effect of microneedle design on pain in human volunteers. Clin J Pain. 2008;24(7):585-94. doi: 10.1097/AJP.0b013e31816778f9, PMID 18716497
Park JH, Allen MG, Prausnitz MR. Biodegradable polymer microneedles: Fabrication, mechanics and transdermal drug delivery. J Control Release. 2005;104(1):51-66. doi: 10.1016/j. jconrel.2005.02.002, PMID 15866334
Lee JW, Park JH, Prausnitz MR. Dissolving microneedles for transdermal drug delivery. Biomaterials. 2008;29(13):2113-24. doi: 10.1016/j.biomaterials.2007.12.048, PMID 18261792
Lee K, Lee CY, Jung H. Drawing lithography: Three-dimensional fabrication of an ultrahigh-aspect-ratio microneedle. Biomaterials. 2011;32(13):3134-40.
Kim M, Jung B, Park JH. Hydrogel swelling as a trigger to release biodegradable polymer microneedles in skin. Biomaterials. 2012;33(2):668-78. doi: 10.1016/j.biomaterials.2011.09.074, PMID 22000788
Kwak HH, Shim WS, Choi MK, Son MK, Kim YJ, Yang HC, et al. Development of a sustained-release recombinant human growth hormone formulation. J Control Release. 2009;137(2):160-5. doi: 10.1016/j.jconrel.2009.03.014, PMID 19332090
Kemp JM, Kajihara M, Nagahara S, Sano A, Brandon M, Lofthouse S. Continuous antigen delivery from controlled release implants induces significant and anamnestic immune responses. Vaccine. 2002;20(7-8):1089-98. doi: 10.1016/s0264-410x(01)00444-3, PMID 11803069
Tsioris K, Raja WK, Pritchard EM, Panilaitis B, Kaplan DL, Omenetto FG. Fabrication of silk microneedles for controlled-release drug delivery. Adv Funct Materials. 2012;22(2):330-5. doi: 10.1002/ adfm.201102012
Wang JJ, Zeng ZW, Xiao RZ, Xie T, Zhou GL, Zhan XR, et al. Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomedicine. 2011;6:765-74. doi: 10.2147/IJN.S17296, PMID 21589644
Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev. 2010;62(1):3-11. doi: 10.1016/j. addr.2009.09.004, PMID 1980037717. Kanauchi O, Deuchi K, Imasato Y, Kobayashi E. Increasing effect of a chitosan and ascorbic acid mixture on fecal dietary fat excretion. Biosci Biotechnol Biochem. 1994;58(9):1617-20. doi: 10.1271/bbb.58.1617
Maezaki Y, Tsuji K, Nakagawa Y, Kawai Y, Akimoto M, Tsugita T, et al. Hypocholesterolemic effect of chitosan in adult males. Biosci Biotechnol Biochem. 1993;57(9):1439-44. doi: 10.1271/bbb.57.1439
Arai K, Kinumari T, Fujita T. Digestibility of chitosan in animals. Bol Tokai Reg Fish Res Lab. 1986;56:889-92.
Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan--DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med. 1999;5(4):387-91. doi: 10.1038/7385, PMID 10202926
Sonaje K, Lin YH, Juang JH, Wey SP, Chen CT, Sung HW. In vivo evaluation of safety and efficacy of self-dissolving microneedles for insulin delivery. Biomaterials. 2009;30(12):2329-39. doi: 10.1016/j. biomaterials.2008.12.066, PMID 19176244
Zhang W, Gao J, Zhu Q, Zhang M, Ding X, Wang X, et al. Penetration and distribution of PLGA nanoparticles in the human skin treated with microneedles. Int J Pharm. 2010;402(1-2):205-12. doi: 10.1016/j. ijpharm.2010.09.037, PMID 20932886
Davis SP, Landis BJ, Adams ZH, Allen MG, Prausnitz MR. Insertion of microneedles into skin: Measurement and prediction of insertion force and needle fracture force. J Biomech. 2004;37(8):1155-63. doi: 10.1016/j.jbiomech.2003.12.010, PMID 15212920
Chu LY, Choi SO, Prausnitz MR. Clinical evaluation of microneedles for transdermal drug delivery. J Pharm Sci. 2010;99(9):4228-38.
Khanna P, Luongo K, Strom JA, Bhansali S. Microneedle-based delivery of doxorubicin for treatment of skin cancer. J Micromech Microeng. 2010;20(4):045011. doi: 10.1088/0960-1317/20/4/045011
Saurer EM, Flessner RM, Sullivan SP, Prausnitz MR, Lynn DM. Layer-by-layer assembly of DNA- and protein-containing films on microneedles for drug delivery to the skin. Biomacromolecules. 2010;11(11):3136-43. doi: 10.1021/bm1009443, PMID 20942396
Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release. 2010;142(2):187-95. doi: 10.1016/j.jconrel.2009.10.013, PMID 19840825
Sullivan SP, Murthy N, Prausnitz MR. Minimally invasive protein delivery with rapidly dissolving polymer microneedles. Adv Mater. 2008;20(5):933-8. doi: 10.1002/adma.200701205, PMID 23239904
Chen XF, Kask AS, Crichton ML, McNeilly C, Yukiko S, Dong L, et al. Improved DNA vaccination by skin-targeted delivery using dry-coated densely-packed microprojection arrays. J Control Release. 2010;148(3):327-33. doi: 10.1016/j.jconrel.2010.09.001, PMID 20850487
Quan FS, Kim YC, Compans RW, Prausnitz MR, Kang SM. Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles. J Control Release. 2010;147(3):326-32. doi: 10.1016/j.jconrel.2010.07.125, PMID 20692307
Koutsonanos DG, Del Pilar Martin M, Zarnitsyn VG, Sullivan SP, Compans RW, Prausnitz MR, et al. Transdermal influenza immunization with vaccine-coated microneedle arrays. PLOS One. 2009;4(3):e4773. doi: 10.1371/journal.pone.0004773, PMID 19274084
Quan FS, Kim YC, Vunnava A, Yoo DG, Song JM, Prausnitz MR, et al. Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J Virol. 2010;84(15):7760-9. doi: 10.1128/JVI.01849-09, PMID 20484519
Andrade F, Antunes F, Nascimento AV, Da Silva SB, Das Neves J, Ferreira D, et al. Chitosan formulations as carriers for therapeutic proteins. Curr Drug Discov Technol. 2011;8(3):157-72. doi: 10.2174/157016311796799035, PMID 21091431
Gajare S, Zalte A, Saudagar RB. Simultaneous spectrophotometric determination of linagliptin and metformin hydrochloride in combined tablet dosage form. Asian J Pharm Anal. 2017;7(2):76-80. doi: 10.5958/2231-5675.2017.00013.8
Gajare S, Das V, Sambherao A, Zalte A, Saudagar RB. Development and validation of linagliptin and metformin hydrochloride in bulk and combined tablet dosage form by using UV spectrophotometric method. Asian J Pharm Anal. 2017;7(2):129-33.
Rao BV, Vijetha P, Vidyadhara S, Kavitha K. A novel RP-HPLC method development and validation for the determination of pioglitazone and glimepiride in bulk and pharmaceutical formulations. Asian J Pharm Anal. 2017;7(2):134-8.
Parmar A, Sonawane S, Chhajed S, Kshirsagar S. Development and validation of RP-HPLC method for simultaneous estimation of ezetimibe and glimepiride in tablet dosage form. Asian J Pharm Anal. 2017;7(3):164-8. doi: 10.5958/2231-5675.2017.00029.1
Swamy GK, Lalitha R, Mounika C, Soumya B, Kumar DS. A validated RP-HPLC method for simultaneous determination of metformin and canagliflozin in pharmaceutical formulation. Asian J Pharm Anal. 2018;8(1):38-42.
Jyothi G, Kumar DS, Bhavani P, Anjiah D, Kumar GS. Eco-friendly spectrophotometric estimation of gliclazide using hydrotropic solubilization technique. Asian J Pharm Anal. 2019;9(1):38-41.
Gadge SS, Nakod AD, Wasnik VP, Gatkine TM, Zile SS, Mohije NH, et al. Development and validation of Q-absorbance ratio method for simultaneous estimation of teneligliptin hydrobromide and metformin HCl in multicomponent dosage form. Asian J Pharm Anal. 2019;9(2):215-8.
Bichala PK, Kumar KJ, Suthakaran R, Shankar C. Development and validation of an analytical method for the estimation of metformin and teneligliptin in its bulk and tablet dosage form by using RP-HPLC. Asian J Pharm Anal. 2020;10(1):11-4. doi: 10.5958/2231- 5675.2020.00003.4
Gupta S, Vasanth D, Kumar A. Fabrication and characterization of dissolving microneedle patch using 3d printed master. Int J Appl Pharm. 2024;16(6):182-9. doi: 10.22159/ijap.2024v16i6.52314
Jalajakshi MN, Chandrakala V, Srinivasan S. An overview: Recent development in transdermal drug delivery. Int J Pharm Pharm Sci. 2022;14(10):1-9. doi: 10.22159/ijpps.2022v14i10.45471
Published
How to Cite
Issue
Section
Copyright (c) 2025 Foram bhatt
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
